-
@ Layer3.news
2025-05-23 05:34:24
nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgr8g2hyzql5lt4cxfjdj40hgtu6vydvsqvsesqy8canygcce3lwvyyapkyy
BERNSTEIN REAFFIRMS PFIZER RATING AFTER $6B CANCER TREATMENT DEAL
https://s.yimg.com/ny/api/res/1.2/1j9KqNbb3IsiOJlw78j4yA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/480d386c68b2d152b91643d254f4d3af
--
✍️ Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. following a $6 billion licensing deal with 3SBio Inc. to develop and market the cancer treatment SSGJ-707.
--
👉 Pfizer Inc. licensed SSGJ-707 from 3SBio Inc. for $6 billion
👉 The deal has raised questions about Pfizer's continued collaboration with Summit Therapeutics
👉 Pfizer plans to produce SSGJ-707 in the United States, aligning with current policy debates over tariffs and domestic production of pharmaceuticals
--
#KenFisher #SteveCohen #business
--
nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgr2fkmnly4zkzvzq2qd5x8pv2stltr5g9u8ze0zkpsw5zsdx8h3hvz2wxgx